1. (Currently Amended) A compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

Y is selected from the group consisting of CO_2H, $CONMe_2$, CONHMe, CONHEt, $CON(OCH_3)CH_3$, $CONH_2$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2CH_3$, SO_2NH_2, $SO_2N(CH_3)_2$, $SO_2NH(CH_3)$,



, and



; and

R is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, CO_2H, OH, COH, $COCH_3$, $COCF_3$, NO_2, CN, and CF_3.

2. (Original) The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

3. (Original) The compound of claim 2 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

4. (Original) The compound of claim 3 consisting of



5. (Original) The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

6. (Currently Amended) A compound having an ω chain ~~comprising~~, said compound having a structure





or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

wherein said derivative has a structure as shown above except that an alteration is made to said structure, wherein an alteration consists of

a. adding, removing, or substituting a non-hydrogen atom of the ω chain;

b. converting a CO_2H to a moiety selected from the group consisting of $CONMe_2$, CONHMe, CONHEt, $CON(OCH_3)CH_3$, $CONH_2$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2CH_3$, SO_2NH_2, $SO_2N(CH_3)_2$, $SO_2NH(CH_3)$,



, and



;

c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or

d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

or a pharmaceutically acceptable salt or a prodrug thereof.

7. (Original) The compound of claim 1 comprising
4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid,
or a pharmaceutically acceptable salt or a prodrug thereof.

8. (Original) The compound of claim 1 consisting of
4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or
4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid.

9. (Currently Amended) A method comprising administering an effective amount of a compound to a mammal, said method being effective in treating or preventing glaucoma or treating intraocular hypertension, wherein said compound comprises



or a pharmaceutically acceptable salt or a prodrug thereof,
wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

Y is selected from the group consisting of CO_2H, $CONMe_2$, CONHMe, CONHEt, $CON(OCH_3)CH_3$, $CONH_2$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2CH_3$, SO_2NH_2, $SO_2N(CH_3)_2$, $SO_2NH(CH_3)$,


, or

; and

R is selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, CO_2H, OH, COH, $COCH_3$, $COCF_3$, NO_2, CN, and CF_3.

10. (Currently Amended) A liquid composition comprising an effective amount of a compound having an ω chain ~~comprising,~~ said compound having a structure





or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

wherein said derivative has a structure as shown above except that an alteration is made to said structure, wherein an alteration consists of

a. adding, removing, or substituting a non-hydrogen atom of the ω chain;

b. converting a CO_2H to a moiety selected from the group consisting of $CONMe_2$, CONHMe, CONHEt, $CON(OCH_3)CH_3$, $CONH_2$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2CH_3$, SO_2NH_2, $SO_2N(CH_3)_2$, $SO_2NH(CH_3)$,



, and



;

c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or

d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

or a pharmaceutically acceptable salt or a prodrug thereof; and

wherein said composition is intended for topical ophthalmic use.